WillItSurvive
Pharma and healthcare groups · United States

CVS Health

cvshealth.com ↗

Pharmacy, insurance, and drug benefits giant with 9,000 stores and 88M PBM members.

Defensible for now
Assessed 30 July 2026 · Evidence as of 30 July 2026
Real protection, with named pressure against it.
On the recordSince 30 July 2026 · Checkable from August 5, 2026 · Every call on the record Checkpoint: Q2 2026 earnings report, includes Aetna Medicare Advantage margin update
The call

CVS's pharmacy-insurer-PBM combination keeps generating cash even as regulators try to pull the pieces apart.

CVS runs nearly 9,000 pharmacies and also owns an insurance company that pays for drugs, giving it unique control over what medicines people buy and how much they cost. This combination is very hard to copy because it requires pharmacy licenses, insurance approval from regulators, and access to millions of customers' prescription records, which Amazon and Walmart do not have. However, the U.S. government is suing CVS to force it to break apart these businesses or change how it makes money, and the company already lost billions of dollars on a failed attempt to build doctor's offices, so the thing that matters most is whether courts decide CVS's vertically integrated model is illegal or just needs to be reformed.

Why
01
AI pressure: None apparent. AI helps CVS run pharmacy workflow and claims processing, but licensed dispensing and PBM contracts stay human-run and regulated. Could AI do the core job? Unlikely.
02
Bigger players: UnitedHealth Group/Optum. Optum runs the same pharmacy plus insurer plus care model at bigger scale and keeps building owned primary care while CVS retreats from that bet. Could a giant copy it? No, they are blocked.
03
What protects it. Licensed pharmacy network plus PBM contracts covering 88 million members create scale and regulatory barriers that new entrants cannot easily cross.
What would change this call
Tennessee FAIR Rx Act litigation outcome and whether other states pass similar vertical-integration bans. Would show regulators can force CVS to unwind the PBM-pharmacy-insurer structure that is its moat.
Aetna Medicare Advantage benefit ratio in Q2 2026 earnings (Aug 5, 2026) versus Humana's 91.2%. Would show whether CVS faces the same MA cost pressure hitting Humana.
Any further Oak Street Health clinic closures or impairments beyond the $5.73B already booked. Would show whether damage is spreading from care-delivery into core insurance/PBM segments.
Key numbers
  • FY2025 revenue $402.067 billion, up 7.85% (2025-12-31)
  • Caremark PBM covers about 88 million members (2026-03-31)
  • Stock near $110.68, up about 85% from 2025 lows (2026-07-29)
Named risks
  • Tennessee FAIR Rx Act litigation could force structural separation of PBM from pharmacy and insurer. Severity: high
  • Florida AG antitrust probe into Caremark practices, documents due July 28, 2026. Severity: medium
  • Medicare Advantage benefit ratio pressure sector-wide could squeeze Aetna margins. Severity: medium
  • Failed $5.73 billion healthcare-delivery expansion signals execution risk in new business lines. Severity: medium
  • Ongoing corporate layoffs and clinic closures could continue depressing headcount and delivery-segment revenue. Severity: low
Rivals, as read in July 2026
RivalDirectionEvidence
UnitedHealth/OptumcontestingDescribed as bigger and more profitable than CVS per July 13, 2026 Trefis comparison; expanding owned primary care as CVS retreated
Humanagaining onQ2 2026 benefit ratio hit 91.2%, reflecting sector-wide Medicare Advantage cost pressure also facing CVS's Aetna
Cigna/Express ScriptscontestingCigna settled FTC insulin-pricing case February 2026, months before CVS Caremark settled in July 2026
Amazon/Walmart pharmacygaining onChipping at mail-order and retail pharmacy fulfillment, prompting CVS's July 2026 small-format store strategy
Independent pharmacy hub providerscontestingGained new FTC-mandated protections against Caremark rebate practices as of July 14, 2026 settlement
Questions people ask
What is CVS Health's biggest risk?
The biggest risk is losing PBM ground to Cigna's Express Scripts, which overtook CVS's Caremark in pharmacy benefit manager claims share after winning a 20-million-member Centene contract in 2024. UnitedHealth's Optum runs the same integrated pharmacy-insurance-PBM model at even larger scale, adding a second front of competition. Amazon Pharmacy is also pressing into the consumer front door, adding further pressure on CVS's retail and PBM position.
Is CVS Health in financial trouble?
No signs point to financial distress. FY2025 total revenue was $402.067 billion (as of 2026-02-10), Q1 2026 revenue was $100.43 billion (2026-07-09), and FY2026 adjusted EPS guidance stands at $7.00 to $7.20 (2026-02-10). Market capitalization ranged $132.9 to $135.1 billion as of 2026-06-29, with shares trading at $107.64 on 2026-07-20, consistent with a large, functioning company rather than one in crisis.
Who are CVS Health's biggest competitors?
The main rivals are Cigna's Express Scripts, which has already taken PBM claims share from CVS's Caremark unit, and UnitedHealth's Optum, which runs the same combined pharmacy-insurance-PBM model at even greater scale. Amazon Pharmacy is also pushing into the consumer front door, and Walgreens remains a struggling but present competitor, currently closing about 1,200 stores over three years. Within its 185-company category as of the July 2026 assessment, CVS still outranks Walgreens but trails the momentum of Express Scripts.
Is CVS Health at risk from AI?
The threat is described as building rather than urgent: AI agents from Amazon, Google's Health100 platform, and health-focused tools from OpenAI or Anthropic want to own scheduling, refills, and benefits navigation. But these tools cannot legally dispense controlled drugs or absorb pharmacist liability, and CVS's roughly 9,000 physical stores and licensed pharmacist dispensing act as a practical shield against full AI replacement. Our July 2026 assessment found little sign that AI tools are close to replacing the pharmacy counter itself.
Can a big tech or insurance giant just copy CVS Health's business model?
That is considered blocked for now. Our July 2026 assessment found that CVS's combination of pharmacy locations, insurance membership, and drug-benefit contracts sets a high bar for any new entrant to replicate from scratch. Still, UnitedHealth's Optum already runs a similar integrated playbook at even larger scale, showing the model can be matched by an existing giant even if it is hard for a newcomer to build.
What should I watch for with CVS Health going forward?
By December 2026, CVS is expected to post a net increase in store count versus FY2025, which would reverse the store-closure trend seen from 2022 through 2025. Also watch the FTC PBM settlement implementation and court-monitor compliance deadlines, which take effect in H2 2026 and directly affect Caremark's regulatory standing. By December 2027, a separate signal to track is whether CVS's Health100 platform signs its first non-CVS pharmacy or insurer partner.
Timeline
  • 2026-07-28Federal judge consolidated four lawsuits, 57 plaintiffs, challenging Tennessee's vertical PBM-pharmacy integration ban
  • 2026-07-23Florida AG opened antitrust probe into CVS/Caremark; documents due July 28, 2026
  • 2026-07-17CVS opened first pharmacy-focused small-format store in Houston, TX
  • 2026-07-14CVS Caremark reached FTC settlement on rebate practices, up to $8.5B consumer savings over 10 years
  • 2026-05-29CVS won Newsweek AI Impact Award for AI-driven prescription interpretation tool
  • 2026-05-06CVS reported Q1 2026 revenue of $100.4B, up 6.2%, raised full-year guidance
  • 2026-04-02Aetna laid off 313 Hartford-based remote workers
  • 2026-03-05CVS and Google Cloud announced Health100 AI-native consumer engagement partnership
  • 2025-11David Joyner named Chairman of CVS Health
  • 2025-10-29CVS took $5.73B impairment, closed 16 Oak Street Health clinics
Head to head
CVS Health vs Walgreens Boots AllianceCVS Health vs UnitedHealth Group
Revision history
30 July 2026
First assessed. Defensible for now. The text above is fixed as of this date and is not edited afterwards.
In the same band
ZoetisBoston ScientificBecton Dickinson
More in Pharma and healthcare groups →
Sources